Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing

Area of Science:

• Genomics and Bioinformatics
• Regulatory Science
• Consumer Health

Background:

• The US Food and Drug Administration (FDA) issued a warning to 23andMe in November 2013, halting marketing of its Personal Genome Service (PGS).
• The FDA classified the PGS as an unclassified medical device requiring premarket approval or de novo classification.
• This action sparked debate regarding consumer rights, regulatory overreach, and the future of direct-to-consumer (DTC) genetic testing.

Purpose of the Study:

• To review the FDA-23andMe incident and its implications.
• To evaluate the challenges and future prospects for DTC genetic testing.
• To analyze the regulatory landscape for consumer genomics.

Main Methods:

• Review of the FDA's regulatory action against 23andMe.
• Analysis of arguments from proponents and opponents of the FDA's decision.
• Examination of the impact on the consumer genomics field and next-generation sequencing applications.

Main Results:

• The FDA's action highlighted regulatory concerns regarding the accuracy and utility of DTC genetic tests.
• The incident revealed a conflict between consumer access to genetic information and regulatory oversight.
• The case underscored the FDA's stance on the medical applications of next-generation sequencing.

Conclusions:

• The FDA-23andMe case serves as a critical juncture for DTC genetic testing regulation.
• Balancing consumer access with safety and efficacy is crucial for the future of the industry.
• Further evaluation is needed to establish clear guidelines for DTC genetic testing services.